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BACKGROUND: Episodes of acute subcutaneous angioedema affecting the extremities in patients with
known hereditary angioedema are called peripheral attacks. These attacks are considered to be of limited
clinical importance.
OBJECTIVE: To evaluate the impact of peripheral attacks in patients with hereditary angioedema and to
assess the response to treatment with recombinant human C1-inhibitor (rhC1INH).
METHODS: Hereditary angioedema patients with a peripheral attack included in a clinical database of
rhC1INH were analyzed. Visual analog scale (VAS) scoring was used to evaluate symptom severity and
response to therapy.
RESULTS: Sixty-five patients with a peripheral attack were identified. VAS scores for 64 patients were
available. Twenty-nine (45%) patients reported a single peripheral location of the attack, the others
multiple locations. Eight patients (13%) indicated moderate (VAS 20-50 mm) and 55 (86%) severe (VAS
50 mm) swelling, 17 (27%) had moderate and 35 (55%) severe pain, while 8 (13%) patients reported
moderate and 51 (80%) severe dysfunction for the peripheral attack. Symptom VAS scores decreased over
time more rapidly in patients treated with rhC1INH than in patients treated with placebo. Onset of relief
was achieved in 95% of the rhC1INH-treated patients within 4 hours, whereas only 21% of saline-treated
patients had relief in the same time period.
CONCLUSION: Peripheral attacks in hereditary angioedema patients often are located at multiple anatomical
locations and frequently have associated pain and dysfunction, in addition to swelling, as dominant
symptoms. The medical need for treatment of these attacks may be underestimated. Treatment with
rhC1INH constitutes a therapeutic option for acute peripheral hereditary angioedema attacks.
© 2012 Elsevier Inc.
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937.e18 The American Journal of Medicine, Vol 125, No 9, September 2012Hereditary angioedema can be caused by an inherited
heterozygous deficiency of the plasma protein C1 es-
terase inhibitor (C1INH).1-3,5,6 This deficiency allows
uncontrolled activation of complement and contact sys-
tem pathways with the release of vasoactive peptides,
such as bradykinin, that mediate the
attacks.7-10 Angioedema attacks are
characterized by a nonpruritic, non-
pitting, subcutaneous or submuco-
sal edema, frequently involving ex-
tremities, the gastrointestinal tract,
the trunk, genitalia, orofacial region,
and sometimes the larynx, and are
often preceded by prodromal symp-
toms.1-4,11 Typically, untreated at-
acks take 2-5 days to resolve. The
requency of attacks varies from
ess than once per year to attacks
very week.1,3
Submucosal attacks in the abdo-
men and in the upper airways are
the most serious clinical manifesta-
tions of hereditary angioedema—
abdominal attacks because they re-
sult in severe pain, nausea, vomit-
ing, and ascites formation, and at-
tacks in the upper respiratory tract because of the risk for
upper airway obstruction and death.1,3,12-14 In contrast, sub-
cutaneous attacks in the skin are often regarded as painless
and clinically insignificant.15 More than 80% of the subcu-
taneous attacks are located on extremities, for example,
hands, feet, arms, and legs, and are therefore often called
peripheral attacks.16,17 Because of their supposed limited
linical impact, peripheral attacks have gained little atten-
ion in the medical literature and are less likely to be treated.
Recombinant human C1INH (rhC1INH, Ruconest/Rhu-
in; Pharming Technologies, Leiden, the Netherlands) is an
fficacious and safe treatment for acute attacks in hereditary
ngioedema.18-21 The studies with rhC1INH have provided
a unique clinical database, as hereditary angioedema pa-
tients recorded a set of symptom visual analog scale (VAS)
scores at various time-points. Here we report an analysis of
various symptoms in patients with an acute peripheral an-
gioedema attack included in this database, and report the
response to rhC1INH treatment as compared with placebo
treatment.
PATIENTS, MATERIALS, AND METHODS
Patients
All patients included in this study participated in clinical
studies on rhC1INH as a treatment for symptomatic hered-
itary angioedema.20,21 Patients were enrolled when they
were older than 12 years, had signed informed consent, and
had a plasma level of functional C1INH50% of normal.21
Patients were allowed to continue maintenance therapy with
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eral angioedema
estimated.
● Recombinant hu
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treatment of sucandrogens or antifibrinolytic drugs, and were asked to pres- dent at a clinical center when they had severe angioedema
symptoms. At presentation, patients were asked to rate the
severity of symptoms and the overall severity by filling in a
set of VAS scores specific for the involved location(s). Four
locations were assessed: abdominal, genitourinary, orofa-
cial-pharyngeal-laryngeal, and pe-
ripheral. Life-threatening laryn-
geal attacks were excluded from
the randomized controlled trial
(RCT) protocols, but were eligible
for open label treatment.
An angioedema attack was eligi-
ble when at presentation the onset
of attack symptoms was 5 hours,
and the overall severity of at least
one location of the attack had been
rated by the patient as 50 mm on
a 100-mm VAS. A peripheral attack
was identified when a patient had
reported in the case record form an
overall severity VAS of 20 mm
for at least one peripheral location.
At presentation (T1 hour), at
the start of study drug infusion
(T0 hours; baseline), and at 15
and 30 minutes, and 1, 2, 4, 8, 12,
6, 24, and 48 hours thereafter, patients were asked to record
set of VAS scores for any of 4 anatomical location(s) at
hich symptoms were present.
For each location, the data collected included the over-
ll severity VAS score and any specific VAS score de-
igned for that location. VAS forms contained a series of
orizontal lines representing continuous scales from 0 to
00 mm, with 0 mm indicating no symptom and 100 mm
he most severe form of a given symptom. Patients were
sked to mark the severity of the various angioedema
ymptoms on each of these lines. The VAS questions
sed for a peripheral location of an angioedema attack are
iven in Table 1. A symptom was considered to be
evere when the patient had scored the severity as 50
m on the VAS, moderate when the score was between
0 and 50 mm, and minimal when a patient had scored
he symptom as 20 mm on the VAS. The time of onset
f relief of a symptom was defined as the first time-point
t which the VAS score had decreased by at least 20 mm
ith respect to baseline and with persistency to the next
ime-point, or at which the severity of the symptom had
een scored as minimal (VAS score 20 mm) by the
atient. Clinical response to therapy was defined as onset
f relief of a symptom occurring, at the latest, at the
ssessment scheduled at 4 hours after start of treatment.
The highest symptom VAS score was the highest score
ecorded by the patient. In case of equal scores, the clini-
ally most serious score was used as the highest symptom
AS score. The order of clinical seriousness was pain,
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937.e19Kusuma et al Clinical Impact of Peripheral Hereditary Angioedema AttacksIn the double-blind placebo-controlled phase of the stud-
ies, which were conducted in Europe and in North America,
patients were randomized to receive treatment with
rhC1INH at 50 or 100 U/kg or saline.22 In the open label
xtension phase of the European study, patients were treated
ith 1 vial of 2100 U, with an option for 1 or 2 additional
ials. In the open label extension phase of the American
tudy, patients were treated with 50 U of rhC1INH per kg,
ith an option for an additional dose of 50 U/kg. A patient
ho experienced onset of relief of symptoms at the latest at
he assessment scheduled at 4 hours after start of treatment,
as considered to have a clinical response to therapy.
Data Analysis
Data normally distributed are expressed as the mean and
SD. Data not normally distributed are given as the median
Table 1 VAS Questions to Assess Symptoms and Overall
Severity of Angioedema Attacks at a Peripheral Location
Question
VAS Score
0 mm 100 mm
Do you have any
swelling?
No swelling Extreme swelling
Do you have pain? No pain Excruciating pain
Do you have impairment
in using the swollen
extremity?
Not at all Extreme
impairment
How severe are the
angioedema symptoms
now for this location?
No symptoms Extremely
disabling
VAS visual analog scale.
Table 2 Characteristics of 65 HAE Patients Identified in the
Clinical Database with an Angioedema Attack Involving At
Least One Peripheral Location
n M/F
Age, Years
(Average)
Weight, kg
(Average)
ll patients 65 20/45 35.1 78.4
atients with an attack
nvolving
Single peripheral
location
29 10/19 34.3 81.1
Multiple peripheral
locations
11 4/7 36.5 74.5
One peripheral
location and
nonperipheral
location(s)
14 2/12 38.1 74.1
Multiple peripheral
locations and
nonperipheral
location(s)
11 4/7 31.2 80.6HAE  hereditary angioedema.and the 25th and 75th percentile. Time to event data is
depicted as Kaplan-Meier plots. Correlation between pa-
rameters was analyzed by calculating Pearson’s correlation
coefficient. Differences in clinical response of patient
groups to treatment were calculated with Fisher’s exact test.
A (2-sided) P-value .05 was considered to represent a
significant correlation or difference.
Figure 1 Hereditary angioedema patients with a peripheral
attack frequently report pain and dysfunction in addition to
swelling of the affected site. Patients were asked to score the
severity of symptoms of the affected peripheral site using a
100-mm visual analog scale (VAS). Score (in mm) is given on
the y-axis. Severe ( 50 mm), moderate (20-50 mm), and
minimal symptoms (20 mm) are indicated by shading.
Squares patients with one peripheral location of the attack;
diamonds patients with multiple peripheral locations;
triangles patients with one peripheral and at least one other
location; circles patients with multiple peripheral and at least
Table 3 Distribution of Locations of the First Peripheral HAE
Attack in 65 HAE Patients
Location n %
All peripheral locations 88 100
Right hand 16 18.2
Right hand arm 7 7.9
Right arm 6 6.8
Right foot 10 11.4
Right leg 2 2.2
Left hand 15 17.1
Left hand arm 3 3.4
eft arm 9 10.3
eft foot 13 14.8
eft leg 1 1.1
ther 6 6.8
HAE  hereditary angioedema.on other location.
SM
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Patients and Attacks Included in the Analysis
At the time the study was performed, the clinical database
contained data of 225 eligible attacks in 119 hereditary
angioedema patients. Eighty-eight of these attacks (Table
2) met the criteria for a peripheral attack as described in
Methods. These 88 attacks had occurred in 65 patients. The
Figure 2 The course of the average ov
(VAS) scores for the peripheral location in
with an attack involving at least one perip
ized controlled trials (RCT). VAS scores
received recombinant human C1-inhibitor
who received saline. The different symbols
Table 4 Symptom VAS Scores at the Time of Evaluation in
HAE Patients with an Attack Involving a Peripheral Location
(n 64)
Symptom n %
evere (VAS 50 mm) Swelling 55 85.9
Pain 35 54.7
Dysfunction 51 79.7
oderate (20 VAS 50 mm) Swelling 8 12.5
Pain 17 26.6
Dysfunction 8 12.5
Minimal (VAS 20 mm) Swelling 1 1.6
Pain 12 18.8
Dysfunction 5 7.8
Highest VAS score for Swelling 24 37.5
Pain 10 15.6
Dysfunction 30 46.9
HAE  hereditary angioedema; VAS  visual analog scale.the inset. Bars indicate the standard error of themean age of these 65 patients was 35 years; 45 patients were
female. Twenty-five patients (38%) used androgens, in par-
ticular, danazol, as maintenance therapy; 3 patients (5%)
used tranexamic acid, including one who also used danazol.
Seventeen patients reported repeated peripheral attacks.
For the present analysis, only the data for the first peripheral
attack were used. In 4 patients, the severity of the peripheral
attack was moderate (overall severity VAS score between
20 and 50 mm). These 4 patients each had another eligible
location of their attack, a facial-oropharyngeal-laryngeal
location in 3 and an abdominal location in one patient. The
affected anatomical sites for the peripheral attacks in the 65
patients are given in Table 3.
In 29 of the 65 (45%) patients, the angioedema attack
occurred at a single peripheral location. In the other 36, the
attack occurred at multiple locations, either at 2 or more
peripheral locations (11 of the 65 [17%] patients) or at one
or more peripheral and one or more nonperipheral locations
(25 [38%] patients) (Table 2). Thus, the majority of the
patients had an attack at multiple locations.
Symptom and Overall Severity VAS Scores
VAS scores at the time of evaluation of one patient with
a peripheral attack were lacking. Results of symptom and
overall severity VAS scores of the other 64 patients with
a peripheral attack at the time of evaluation (T1
hour) are given in Figure 1. Sixty-three of the 64 (98%)
everity and symptom visual analog scale
ptomatic hereditary angioedema patients
ocation, who participated in the random-
sed more rapidly in the 22 patients who
INH; solid lines) than in the 14 patients
te the different symptoms as explained inerall s
36 sym
heral l
decrea
(rhC1
indicamean.
937.e21Kusuma et al Clinical Impact of Peripheral Hereditary Angioedema Attackspatients indicated a moderate (20 mmVAS 50 mm)
or severe (VAS 50 mm) swelling for the peripheral
attack (Table 4). Fifty-two patients (81%) indicated a
moderate or severe pain, whereas 59 patients (92%) in-
dicated moderate or severe dysfunction for the affected
peripheral site. Case records indicated that, in individual
patients, severe dysfunction implied that a patient could
not use her/his hand, for example, to write, in the case of
a location in a hand; or was unable to walk on the
affected foot, in the case of location in a foot. The highest
symptom VAS score was that for swelling in 24 (38%)
patients, that for pain in 10 (16%) patients, and that for
dysfunction in 30 (47%) patients (Table 4). Only 3 (5%)
patients had a peripheral attack with just swelling and
minimal or no (VAS 20 mm) pain and dysfunction.
Significant correlations between each of the symptom
VAS scores and the overall severity VAS score were
observed (r 0.70, P .0001 for swelling; r 0.46,
P .0001 for pain; and r 0.75, P .0001 for
dysfunction).
Course of VAS Scores
Of the 65 hereditary angioedema patients with a peripheral
attack, 36 participated in the randomized controlled trial.
Twenty-two patients were treated with rhC1INH (15 with
Figure 3 Recombinant human C1-inhi
relief of symptoms of a peripheral attack
Kaplan-Meier plots of time (hours) to ons
symptom-specific visual analog scale (VA
acute peripheral attack who received rhC1
that only patients with a VAS 50 mm
included in this analysis. The number of p
inset.100 U/kg, 7 with 50 U/kg), whereas 14 received saline. Thecourse of the average overall severity and the symptom
VAS scores in these 2 groups of patients is shown in Figure
2. The VAS scores in the rhC1INH-treated patients de-
creased much faster after study drug administration than in
the saline group. Kaplan-Meier plots of time to beginning of
relief of symptoms and of time to minimal symptoms of
pain, dysfunction, swelling, and overall severity further
illustrated the shorter times to event in the patients treated
with rhC1INH in the randomized controlled trial (Figures
3, 4). The median time to onset of relief was about 2 hours
for any of the symptoms in the patients treated with
rhC1INH, whereas in the saline group it was 10 to 12 hours.
Ninety-five percent of the patients treated with rhC1INH
reported onset of relief of any of the symptoms within 4
hours after study drug administration, versus 21% in the
saline group (Table 5). This difference in clinical response
rate between rhC1INH- and saline-treated patients was
highly significant for each symptom (Table 5). Also, min-
imal symptoms occurred much faster in the rhC1INH-
treated patients than in the saline-treated patients (Figure 4,
Table 5).
Twenty-nine patients received open label treatment with
rhC1INH (14 patients 50 U/kg, 8 patients one vial of 2100
U, 7 patients 2 or 3 vials of 2100 U). These patients reported
similar responses to treatment as the patients treated with
rhC1INH) shortens the time to onset of
reditary angioedema patients. Shown are
lief of symptoms by overall severity and
hereditary angioedema patients with an
solid lines) or saline (dotted lines). Note
he indicated symptom at baseline were
included in each curve is indicated in thebitor (
in he
et of re
S) in
INH (
for t
atientsrhC1INH in the randomized controlled trial. (Table 5).
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Although peripheral attacks constitute more than half of the
angioedema attacks in patients with hereditary angio-
edema,16 the symptoms and clinical impact of these attacks
re poorly described in the medical literature, possibly be-
ause attacks at these sites are considered to be of limited
linical significance.15,17 We evaluated to what extent he-
editary angioedema patients with peripheral attacks suffer,
n addition to swelling, from pain and dysfunction of the
ffected anatomical site, and we assessed the clinical re-
ponse of symptoms to treatment with rhC1INH. Our study
evealed 3 main findings. First, more than 80% of the
atients with a severe peripheral angioedema attack indicate
oderate to severe dysfunction and pain of the affected site,
mplying that, for example, they might be unable to walk in
ase of an affected foot or leg, or unable to write or use their
ands otherwise during the attack. This contrasts with the
eneral assumption that peripheral angioedema is painless
nd of limited clinical significance. Second, we show that
eripheral hereditary angioedema attacks often involve mul-
iple locations at the same time. Third, treatment with
hC1INH effectively shortens the times to onset of relief
nd to minimal symptoms for all symptoms of a peripheral
ttack.
VAS scoring is a sensitive, reliable, and valid tool for
valuating patient-reported outcome measures such as
ain.23-25 In this study, patients recorded VAS scores for
Figure 4 Recombinant human C1-inhi
symptoms of a peripheral attack in hered
Meier plots of time (hours) to minimal sym
visual analog scale (VAS) in hereditary ang
who received rhC1INH (solid lines) or sal
VAS 50 mm for the indicated symptom
number of patients included in each curveain, swelling, and dysfunction at 2 time points before 6reatment: at the time of evaluation and approximately 1
our later, just before administration of study medication.
he change in symptom VAS score between these 2 time-
oints was 10 mm in 64% of the patients, supporting
hat VAS score is sensitive and has a good test-retest reli-
bility as a patient-reported outcome.
A VAS score of approximately 30 mm on a 100-mm
cale corresponds with moderate pain, and a score of ap-
roximately 54 mm or more with severe pain.26 We used a
score of 50 mm on a scale of 100 mm to indicate that a
symptom is severe, and a symptom was labeled as minimal
when the patient scored a symptom 20 mm on a 100-mm
VAS. Similarly, a variation in VAS score of 13 to 16 mm
has been found to represent a clinically significant differ-
ence in the patient’s experience of pain,24,25 and in the study
eported here, a decrease of 20 mm by pain VAS at a
iven time-point compared with baseline was considered
ndicative of a clinically significant improvement of pain.
uch a decrease compared with baseline VAS score was
onsidered to reflect beginning of relief of pain. A similar
pproach was used to indicate beginning of relief of swell-
ng and beginning of relief of dysfunction.
VAS scores of pain, dysfunction, and swelling at evalu-
tion all correlated with the overall severity VAS score and
ith each other. The importance of pain and dysfunction to
he rating of the overall severity of the peripheral attack by
atients was supported by the observation that in 40 of the
rhC1INH) shortens the time to minimal
ngioedema patients. Shown are Kaplan-
by overall severity and symptom-specific
a patients with an acute peripheral attack
tted lines). Note that only patients with a
eline were included in this analysis. The
icated in the inset.bitor (
itary a
ptoms
ioedem
ine (do
at bas4 patients (63%), pain and dysfunction were dominant
rr
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937.e23Kusuma et al Clinical Impact of Peripheral Hereditary Angioedema Attackssymptoms, whereas in the remaining 24 patients, swelling
was more dominant.
A systematic analysis of the occurrence of multiple lo-
cations of attacks in hereditary angioedema is, to our knowl-
edge, lacking, although it is recognized that attacks may
occur at multiple locations.1 Thirty-six (55%) patients with
a peripheral attack described here had one or more other
locations of the attack in addition to the peripheral location.
Also, the majority of repeat peripheral attacks (17 of the 23
[74%]) occurred at multiple locations (data not shown). This
high frequency of multiple locations suggests that periph-
eral attacks in hereditary angioedema result from a systemic
disturbance of homeostatic mechanisms rather than from a
local biochemical activation process triggering the attack.
Indeed, acute attacks of hereditary angioedema are accom-
panied by biochemical phenomena such as cleavage and
depletion of the total circulating pool of high-molecular-
weight kininogen.22,27 However, multiple local activation
processes, as opposed to a systemic activation process, also
may explain multiple locations of an acute angioedema
attack.
The course of the peripheral attacks in the patients that
received saline in the randomized controlled trial may be
indicative of the natural course of a peripheral attack in
hereditary angioedema. In the majority of these patients,
symptoms did not diminish until at least 8-9 hours after
presentation at the clinical site. rhC1INH markedly short-
Table 5 Overview of Time to Onset of Relief, Response Rate, a
Peripheral Attacks in HAE Patients Treated with rhC1INH or Salin
Time to Onset of Relief
(Minutes)
n* Median 25% 75%
hC1INH RCT (n 22)
Swelling 22 124 90 134
Pain 19 123 60 134
Dysfunction 21 122 60 136
Overall 22 122 63 135
hC1INH OLE (n 29)
Swelling 29 120 60 235
Pain 23 71 34 130
Dysfunction 26 120 60 224
Overall 29 120 60 240
aline (n 14)
Swelling 14 720 553 1100
Pain 10 720 553 780
dysfunction 14 639 485 721
overall 14 639 485 721
HAE hereditary angioedema; OLE open label extension; RCT ran
Data are from patients treated with rhC1INH in the randomized contro
patients treated with saline in the RCT.
*Patients whose VAS score was 20 mm at the time of study drug a
†The number (%) of patients who reported a 20 mm improvement
hours (scheduled time) after study drug administration.
‡Two-sided Fisher’s exact test for comparison with saline group.ened the duration of symptoms of the peripheral attack, with95% of the patients experiencing onset of relief (overall
severity) within 4 hours after start of treatment in the ran-
domized controlled trial, in contrast to only 21% of the
saline-treated patients. This effect of rhC1INH on the symp-
toms of peripheral attacks was supported by the findings
from the open label studies. The doses of rhC1INH evalu-
ated ranged from a single vial of 2100 U (approximately
20-40 U/kg) in the open label studies to 100 U/kg in the
randomized controlled trial. We did not analyze the effect of
dose on the efficacy of rhC1INH to mitigate symptoms of a
peripheral attack, because dose subgroups would be too
small for such an analysis. However, as discussed else-
where,28 the optimal dose for C1INH therapy is 50 U/kg,
with lower doses being effective, but in a smaller percentage
of the patients.
In conclusion, severe peripheral attacks of hereditary
angioedema frequently lead to pain and dysfunction of the
affected site, and not only to swelling. In addition, the
majority of these attacks occur at multiple locations. There-
fore, acute peripheral attacks in hereditary angioedema are
a more serious clinical condition than generally assumed,
and warrant clinical intervention. rhC1INH constitutes an
effective therapeutic option for such attacks.
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